Urine Liquid Biopsy Test Provides EGFR Status to Inconclusive Tissue Biopsy

in Press Releases August 17, 2016

Trovagene, Inc., a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced today that a patient case report featuring use of the Company’s Trovera™ EGFR urine-based liquid biopsy test was recently published in Experimental Hematology & Oncology. Dr. David Berz, medical oncologist at the Beverly Hills Cancer Center in Beverly Hills, CA, authored the manuscript titled, Non-invasive Urine Testing of EGFR Activating Mutation and T790M Resistance Mutation in Non-Small Cell Lung Cancer: A Case Report

“This patient case highlights a common clinical scenario when multiple tissue biopsies were completed and failed to obtain critical clinical information, and supports the use of ctDNA from a urine sample to confirm the presence of the EGFR T790M resistance mutation in non-small cell lung cancer,” stated Dr. Berz. “Obtaining serial tissue biopsies, especially in the secondary resistance setting is associated with multiple medical and logistical challenges. Utilizing ctDNA for molecular analysis can overcome these challenges, provide important information, and aid in therapeutic decision-making.”

Timeline of therapy, diagnostic evaluation, and patient status

Dr. Mark Erlander, Chief Scientific Officer at Trovagene added. “Trovera™ is the only urine liquid biopsy test that offers healthcare providers a truly noninvasive alternative to tissue biopsy to obtain clinically actionable information about the cancer and select the most appropriate therapy for their patients.”

Source – PRNewswire

Berz D, Raymond VM, H. Garst JH, Erlander MG. (2016) Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer. Experimental Hematology & Oncology 5:24. [article]

Related News – BCBS Illinois to Cover Trovagene Liquid Biopsy Tests